Austin, TX-based Mirna Therapeutics became more connected and invigorated with the appointment of biopharmaceutical titan Clay B. Siegall to their Board of Directors.
Siegall is well known in the industry for innovative work regarding cancer research and treatment. Mirna will certainly benefit from his expertise in the field while developing their extensive line of cancer treatment products.
The name Mirna is derived from the term microRNA which is used to describe genetic control switches in the body that could one day lead to a cure for cancer. MicroRNA is one of the most progressive areas of cancer treatment with the potential to eliminate the disease that has plagued mankind for millennia.
With Clay Siegall’s leadership and connections, Mirna is positioned to be on the cutting edge of cancer therapy. They already have a number of products in the pipeline with more to come in the future.
Siegall is best known for his leadership role at Seattle Genetics, which he co-founded back in 1998. The Seattle-based company has already created a diverse line of antibody-based treatments previously unavailable to cancer patients. Siegall also serves on the Board of Directors for Alder BioPharmaceuticals, creating another important link between biotech companies on the front lines of cancer treatment.
Siegall’s previous accomplishments include a Ph.D. in genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He also contributed to the National Cancer Institute and the Squibb Pharmaceutical Research Institute, along with a handful of other biotech companies. On top of his epic resume, he has also been published over 70 times and holds 15 patents.
There’s no doubt that Clay Siegall’s extensive experience and insight will help steer Mirna in the right direction moving forward. His ability to secure venture capital will also provide the company with the much-needed funding to continue their research efforts.